Terns Pharmaceuticals (TERN) Projected to Post Earnings on Thursday

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Terns Pharmaceuticals to post earnings of ($0.30) per share for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last released its earnings results on Monday, March 30th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.06. On average, analysts expect Terns Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Terns Pharmaceuticals Stock Performance

TERN stock opened at $52.95 on Thursday. Terns Pharmaceuticals has a one year low of $2.65 and a one year high of $53.19. The stock has a market capitalization of $6.12 billion, a PE ratio of -51.41 and a beta of -0.37. The company has a fifty day moving average of $49.45 and a 200-day moving average of $37.59.

Wall Street Analyst Weigh In

TERN has been the subject of several recent analyst reports. HC Wainwright reiterated a "neutral" rating and issued a $53.00 price objective (down from $60.00) on shares of Terns Pharmaceuticals in a research note on Wednesday, March 25th. Citizens Jmp cut shares of Terns Pharmaceuticals from a "market outperform" rating to a "hold" rating in a research note on Thursday, March 26th. TD Cowen cut shares of Terns Pharmaceuticals from a "buy" rating to a "hold" rating and set a $53.00 price objective for the company. in a research note on Thursday, March 26th. Oppenheimer reiterated a "market perform" rating and issued a $58.00 price objective on shares of Terns Pharmaceuticals in a research note on Monday, April 27th. Finally, Wall Street Zen cut shares of Terns Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Terns Pharmaceuticals has an average rating of "Hold" and a consensus target price of $55.14.

Insider Transactions at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 14,583 shares of Terns Pharmaceuticals stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $46.71, for a total transaction of $681,171.93. Following the completion of the transaction, the chief executive officer owned 288,976 shares in the company, valued at approximately $13,498,068.96. The trade was a 4.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Emil Kuriakose sold 942 shares of Terns Pharmaceuticals stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $52.75, for a total transaction of $49,690.50. Following the transaction, the insider owned 105,673 shares of the company's stock, valued at approximately $5,574,250.75. The trade was a 0.88% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 30,108 shares of company stock valued at $1,302,370. 1.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Terns Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TERN. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Terns Pharmaceuticals during the fourth quarter worth about $25,000. Engineers Gate Manager LP acquired a new position in Terns Pharmaceuticals during the second quarter worth about $41,000. Canada Pension Plan Investment Board acquired a new position in Terns Pharmaceuticals during the second quarter worth about $46,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Terns Pharmaceuticals during the first quarter worth about $51,000. Finally, Polymer Capital Management US LLC purchased a new stake in shares of Terns Pharmaceuticals during the third quarter worth about $76,000. Institutional investors and hedge funds own 98.26% of the company's stock.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.